Insulin Aspart Market Report 2026

Insulin Aspart Market Overview

• Insulin Aspart market size has reached to $3.6 billion in 2025 • Expected to grow to $4.9 billion in 2030 at a compound annual growth rate (CAGR) of 6.3% • Growth Driver: Rising Diabetes Prevalence Driving The Growth Of The Market Due To Increasing Demand For Effective Blood Sugar Management • Market Trend: Technological Advancements Driving Affordable And Accessible Insulin Aspart Solutions Through Biosimilars • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Insulin Aspart Market?

Insulin aspart is a fast-acting insulin analog used to help manage blood sugar levels in people with diabetes. It starts working within 10 to 20 minutes after injection, reaches its peak effect in about 1 to 3 hours, and remains active for about 3 to 5 hours. This makes insulin aspart effective for quickly lowering blood sugar after meals, supporting better overall glucose control. The main types of insulin aspart are human insulin and analog insulin. Human insulin is a hormone produced by the pancreas that regulates blood sugar levels by facilitating the uptake of glucose into cells, and it is commonly used medically to manage diabetes. Human insulin serves as a benchmark in the insulin, helping position insulin aspart as a faster-acting and more effective alternative for diabetes management. The various product types include vials, pre-filled pens, and cartridges used for varied applications such as type 1 diabetes, type 2 diabetes, and gestational diabetes for different end users, including hospitals, home care, specialty clinics, diabetes care centers, and others.

What Is The Insulin Aspart Market Growth Forecast?

The insulin aspart market size is expected to see strong growth in the next few years. It will grow to $4.9 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to global diabetes burden growth, demand for fast-acting insulin, advanced insulin delivery systems, personalized diabetes care, outpatient insulin therapy expansion. Major trends in the forecast period include rising adoption of rapid-acting insulin analogs, increased use of pre-filled insulin delivery devices, expansion of intensive insulin therapy regimens, growing preference for mealtime glycemic control, improved patient compliance through flexible dosing.

What Is The Driver Of The Insulin Aspart Market?

The rising prevalence of diabetes is expected to propel the growth of the insulin aspart market going forward. Diabetes refers to a chronic medical condition characterized by high levels of sugar (glucose) in the blood due to the body's inability to produce or effectively use insulin. The rising diabetes prevalence is due to sedentary lifestyles and unhealthy diets high in sugar and processed foods, which contribute to obesity and insulin resistance. Insulin aspart helps address the rising prevalence of diabetes by offering rapid-acting insulin that effectively controls blood sugar spikes after meals, thereby improving overall blood glucose management in diabetic patients. For instance, in March 2025, according to the report published by the Office for Health Improvement and Disparities, a UK-based government department, the recorded prevalence of type 2 diabetes among adults aged 17 and over in England was 7.0% as of March 2024, up from 6.8% in March 2023. Therefore, the rising diabetes prevalence is driving the insulin aspart industry.

Key Players In The Global Insulin Aspart Market

Major companies operating in the insulin aspart market are Sanofi S.A., AstraZeneca plc, Novo Nordisk A/S, Cipla Limited, Lupin Limited, Zhejiang Hisun Pharmaceutical Co Ltd., Biocon Limited, Amphastar Pharmaceuticals Inc., Civica Inc., Wockhardt Limited, Gulf Pharmaceutical Industries PSC (Julphar), GEROPHARM LLC, HEC Pharm Co Ltd., USV Private Limited, Aqlivia Private Limited, Gan & Lee Pharmaceuticals Co Ltd., GeneSys Biologics Private Limited, Biogenomics Limited, MJ Biopharma Private Limited, Paras Biopharmaceuticals Finland Oy.

Global Insulin Aspart Market Trends and Insights

Major companies operating in the insulin aspart market are increasingly focusing on developing innovative products, such as biosimilars, to provide cost-effective alternatives and enhance patient access to high-quality insulin therapies. A biosimilar refers to a biologic medical product that is highly similar to an already approved reference biologic, with no clinically meaningful differences in terms of safety, purity, or effectiveness. For instance, in November 2023, USV Pvt Ltd, an India-based pharmaceutical company, launched INSUQUICK, India’s first biosimilar insulin aspart, marking a significant milestone in diabetes care in the country. INSUQUICK is a rapid-acting insulin analog, developed and manufactured entirely in India using 100% indigenous technology, and has undergone a rigorous clinical program to meet global quality standards. The pens are designed with a legible scale and audible clicks for precise dosing, and the product is widely accessible across all metropolitan areas as well as tier I and II cities. INSUQUICK aims to improve treatment accessibility for India’s large diabetic population by offering a high-quality, locally produced, and more affordable rapid-acting insulin alternative, marking a significant step in enhancing diabetes care in the country.

What Are Latest Mergers And Acquisitions In The Insulin Aspart Market?

In March 2025, Biocon Biologics, an India-based biopharmaceutical company, partnered with Civica Inc. to enhance the affordability and accessibility of insulin aspart in the United States by supplying the drug substance to Civica, which will manufacture and commercialize the insulin aspart domestically, thereby addressing the critical need for cost-effective diabetes treatment. Civica Inc. is a US-based pharmaceutical company involved in the production and distribution of insulin aspart.

What Defines the Insulin Aspart Market?

The insulin aspart market consists of sales of rapid-acting insulin analogs, biosimilar insulin aspart formulations, pre-filled insulin pens, vial-based insulin solutions, and combination insulin products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Insulin Aspart Market Report 2026?

The insulin aspart market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the insulin aspart industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.